Press Releases Longeveron Inc.

Equities

LGVN

US54303L2034

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.75 ^USD	+4.79%		-8.85%	-87.13%

Apr. 15	Top Premarket Gainers	MT
Apr. 08	Top Premarket Gainers	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Longeveron to Present at the Planet MicroCap Showcase	Apr. 25	AQ
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering	Apr. 18	AQ
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds	Apr. 17	AQ
Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation	Apr. 16	AQ
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)	Apr. 15	AQ
Longeveron Announces Closing of $5.2 Million Public Offering	Apr. 11	AQ
Longeveron Announces Pricing of $5.25 Million Public Offering	Apr. 08	AQ
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals	Apr. 08	AQ
Longeveron Announces 1-for-10 Reverse Stock Split	Mar. 19	AQ
Longeveron Reports Year-End 2023 Results and Provides Corporate Update	Feb. 27	AQ
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024	Feb. 21	AQ
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™	Jan. 29	AQ
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	Dec. 21	AQ
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease	Dec. 20	AQ
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Wa’el Hashad, CEO of Longeveron Inc.	Nov. 14	AQ
Long-term Survival Data from Longeveron’s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association	Nov. 11	AQ
Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update	Nov. 10	AQ
Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023	Nov. 03	AQ
Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for the Treatment of Mild Alzheimer’s	23-10-24	AQ
Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	23-10-13	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Longeveron Inc.

Equities

LGVN

US54303L2034

Press Releases

Filters